Welcome to our dedicated page for Tactile Systems SEC filings (Ticker: TCMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tactile Systems Technology, Inc. (Tactile Medical) SEC filings page for ticker TCMD provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology company incorporated in Delaware, Tactile Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K under Commission File Number 001-37799.
Through these filings, investors can review detailed information on Tactile Medical’s business, including its focus on at-home therapies for lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. Periodic reports describe revenue from sales and rentals of the lymphedema product line and sales of the airway clearance product line, along with discussions of gross margin, operating expenses, net income or loss and non-GAAP measures such as Adjusted EBITDA as defined by the company.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and the authorization of share repurchase programs for the company’s common stock. These filings may include information on the size and duration of repurchase authorizations and the company’s intention to fund them from cash and future cash flows.
On Stock Titan, TCMD filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight key points from lengthy documents, helping users quickly understand topics such as segment performance, capital allocation decisions and risk factor discussions without reading every page. Users can also review insider-related filings, including Forms 3, 4 and 5, to track equity transactions by directors and officers, and proxy statements on Schedule 14A for information on governance and executive compensation.
Whether you are analyzing Tactile Medical’s financial history, monitoring new 8-K disclosures or looking for details on its at-home therapy business, this page centralizes the company’s official SEC filings with concise AI-generated insights.
Kristie Burns submitted a Form 144 notice to sell common stock. The filing lists 4,439 shares tied to restricted stock vesting on 02/20/2026 and shows $125,610.38 alongside a Fidelity brokerage record. It also reports 5,139 shares sold on 01/02/2026 for $148,260.15.
Tactile Systems Technology, Inc. reports full-year 2025 results and provides a detailed overview of its medical technology business focused on at-home treatment of chronic diseases. The company generated $329.5 million in revenue and $19.1 million in net income for 2025, with revenue growing 12% year over year.
Lymphedema products, including Flexitouch Plus, Entre Plus and Nimbl, produced $278.4 million or 84% of 2025 revenue, while the AffloVest airway clearance product line contributed $51.1 million or 16%. Tactile highlights broad U.S. reimbursement coverage, in‑network payer contracts covering about 278 million lives, and a largely direct-to-patient model for lymphedema alongside a DME distribution model for AffloVest.
The filing emphasizes extensive clinical evidence supporting Flexitouch, Nimbl and AffloVest, ongoing R&D investment of $8.5 million in 2025, and a sizable commercial organization with 166 account managers and 185 specialists as of December 31, 2025. Management also outlines significant market opportunities in lymphedema, chronic venous insufficiency and bronchiectasis, while detailing the regulatory, reimbursement and fraud-and-abuse frameworks governing its operations.
Tactile Systems Technology, Inc. reports full-year 2025 results and provides a detailed overview of its medical technology business focused on at-home treatment of chronic diseases. The company generated $329.5 million in revenue and $19.1 million in net income for 2025, with revenue growing 12% year over year.
Lymphedema products, including Flexitouch Plus, Entre Plus and Nimbl, produced $278.4 million or 84% of 2025 revenue, while the AffloVest airway clearance product line contributed $51.1 million or 16%. Tactile highlights broad U.S. reimbursement coverage, in‑network payer contracts covering about 278 million lives, and a largely direct-to-patient model for lymphedema alongside a DME distribution model for AffloVest.
The filing emphasizes extensive clinical evidence supporting Flexitouch, Nimbl and AffloVest, ongoing R&D investment of $8.5 million in 2025, and a sizable commercial organization with 166 account managers and 185 specialists as of December 31, 2025. Management also outlines significant market opportunities in lymphedema, chronic venous insufficiency and bronchiectasis, while detailing the regulatory, reimbursement and fraud-and-abuse frameworks governing its operations.
Tactile Systems Technology reported strong fourth quarter and full-year 2025 results and announced a strategic acquisition. Fourth quarter revenue rose 21% to $103.6 million, with operating income up to $18.8 million and net income of $10.6 million, or $0.46 per diluted share. Full-year 2025 revenue grew 12% to $329.5 million, driven by 7% growth in lymphedema products and 52% growth in airway clearance products. Net income increased to $19.1 million and Adjusted EBITDA rose to $44.8 million, reflecting improved profitability.
The company ended 2025 with $83.4 million in cash and no debt after repaying $26.3 million of term loan borrowings and repurchasing $26.5 million of stock. For 2026, it guides revenue to $357–$365 million and Adjusted EBITDA to $49–$51 million, implying continued growth. Separately, Tactile Medical acquired LymphaTech Inc. for an upfront cash payment of $6.8 million plus potential milestone-based consideration, adding a 3D digital measurement platform to deepen its lymphedema solutions portfolio.
Tactile Systems Technology reported strong fourth quarter and full-year 2025 results and announced a strategic acquisition. Fourth quarter revenue rose 21% to $103.6 million, with operating income up to $18.8 million and net income of $10.6 million, or $0.46 per diluted share. Full-year 2025 revenue grew 12% to $329.5 million, driven by 7% growth in lymphedema products and 52% growth in airway clearance products. Net income increased to $19.1 million and Adjusted EBITDA rose to $44.8 million, reflecting improved profitability.
The company ended 2025 with $83.4 million in cash and no debt after repaying $26.3 million of term loan borrowings and repurchasing $26.5 million of stock. For 2026, it guides revenue to $357–$365 million and Adjusted EBITDA to $49–$51 million, implying continued growth. Separately, Tactile Medical acquired LymphaTech Inc. for an upfront cash payment of $6.8 million plus potential milestone-based consideration, adding a 3D digital measurement platform to deepen its lymphedema solutions portfolio.
Cadian Capital filed an amended Schedule 13G/A showing passive ownership in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Cadian Capital Management, its general partner, and Eric Bannasch were deemed to beneficially own 1,084,094 shares, or about 4.9% of the outstanding common stock.
All shares are held by advisory clients of Cadian Capital Management, over which the adviser has shared voting and investment power. The filing certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Cadian Capital filed an amended Schedule 13G/A showing passive ownership in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Cadian Capital Management, its general partner, and Eric Bannasch were deemed to beneficially own 1,084,094 shares, or about 4.9% of the outstanding common stock.
All shares are held by advisory clients of Cadian Capital Management, over which the adviser has shared voting and investment power. The filing certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Paradigm Capital Management, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Paradigm beneficially owned 736,599 shares, representing 3.29% of the company’s common stock, with sole voting and dispositive power.
The firm states the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Tactile Systems Technology.
Morgan Stanley and Morgan Stanley Capital Services LLC have disclosed significant passive stakes in Tactile Systems Technology Inc. common stock. As of 12/31/2025, Morgan Stanley reports beneficial ownership of 1,293,289 shares, representing 5.8% of the class, with all voting and dispositive power shared.
Morgan Stanley Capital Services LLC reports beneficial ownership of 1,154,700 shares, or 5.2% of the class, also with shared voting and dispositive power. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of Tactile Systems Technology Inc common stock. Dimensional is reported as having beneficial ownership of 1,095,235 shares, representing 4.9% of the outstanding common stock as of the event date of 12/31/2025. It has sole voting power over 1,069,882 shares and sole dispositive power over 1,095,235 shares.
The shares are owned by various funds and accounts that Dimensional advises or manages, and Dimensional disclaims beneficial ownership beyond what is required for Section 13(d) reporting. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology Inc.
Tactile Systems Technology’s Senior Vice President of Marketing & Clinical Affairs, Kristie Burns, reported a planned sale of company stock. On January 2, 2026, she sold 5,139 shares of common stock at a price of $28.85 per share under transaction code “S,” which indicates a sale. After this trade, she beneficially owned 72,401 shares of Tactile Systems Technology common stock in direct ownership.
The sale was made pursuant to a Rule 10b5-1(c) trading plan, which the disclosure notes was adopted on September 11, 2025. Such plans allow insiders to prearrange trades of company stock according to preset instructions, helping separate personal trading decisions from access to inside information.